anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Participants will be treated with adjuvant intralesional TAC 40mg/mL 7-10 days post-op and then every 4 weeks for a total of 3 injections. Assessments will be performed at 3, 6, 9, and 12 months after completion of treatment. At each time point, a member of the study team and patient will complete their respective portion of the Patient and Observer Scar Assessment Scale (POSAS).
Obesity is a risk factor for a number of serious medical comorbidities and is second only to smoking as the leading cause of preventable death in the US. Further, estimates of the costs associated with overweight and obesity have topped $200 billion annually. The numbers are particularly alarming for adolescents, in whom the rate of obesity has risen at 2-3 times as quickly as in adults. Despite the urgent need, very few clinical centers offer obesity treatment due to the resource-intensive nature of most interventions and the fact that behavioral obesity interventions have rarely been reimbursed by 3rd party payers. Following the American Medical Association's recent decision to recognize obesity as a disease and establish ICD-10-CM Diagnosis Codes (e.g., E66.0), however, there is increasing pressure for 3rd party payers to reimburse for effective obesity interventions. Thus, it is critical to identify effective treatment options that can be implemented in medical centers. Prior research has shown meal replacement-based diets to be more effective than typical "lifestyle-change" diet programs, both in terms of weight loss and, more importantly, weight loss maintenance. Evidence also suggests that solid meal replacements (e.g., bars) show greater effectiveness than liquid meal replacements (e.g., shakes). Finally, greater effectiveness is seen with meal replacements that are higher vs. lower in protein. Importantly, these interventions show high rates of effectiveness even in the absence of nutritional counseling, suggesting that a solid meal-replacement based diet program that is relatively high in protein could be highly effective and easily implemented in clinical settings. In this pilot study, 90 adolescents will be randomized to either a meal replacement-based diet (experimental) group or an educational video (comparison) group.

All recruitment and study procedures will take place at the Mount Sinai Adolescent Health Center (MSAHC). The MSAHC is the largest adolescent-specific, integrated, primary care facility in the U.S., and is a unique model that integrates medical, sexual, reproductive, mental health and health education services. MSAHC provides inner-city youth ages 10-24 who are predominately youth of color high quality, comprehensive, easily accessed, free services. Flyers will be posted in the clinic of the Mount Sinai Adolescent Health Center.

At the baseline assessment following recruitment, participants will provide informed consent and complete a structured interview conducted by research staff to more formally assess eating patterns and eating disorders symptomatology. Assessors will conduct interviews at the MSAHC on an individual basis. If a patient meets criteria for an eating disorder, s/he will be referred to treatment. Participants will be randomly assigned to one of two groups using the coin flipper function available at www.random.org. All files will be password protected to prevent unauthorized access of data.
Five times per day for 6 weeks subjects will dissolve an placebo tablet into water and drink the effervescent water. The effervescent placebo tablet does not generate hydrogen-enriched water.
The invention relates to a Chinese patent medicine for treating mammitis and mastocarcinoma and a preparation method thereof, belonging to the field of traditional Chinese medicines. The Chinese patent medicine comprises a medicine for oral use and a medicine for external application. The medicine for oral use is prepared from the following raw material medicines in parts by weight: 150-300 parts of cornu cervi degelatinatum, 15-30 parts of beeswax, 60-120 parts of prepared joss robe, 150-300 parts of prepared tortoise plastron which are mixed and crushed and sieved by a #7 sieve to powder as a finished product. The medicine for external application is prepared from the following raw material medicines in parts by weight: 20-40 parts of radix angelicae, 20-40 parts of rhizoma cyperi, 15-30 parts of flos caryophylli, 15-30 parts of keel, 15-30 parts of rheum officinale, 15-30 parts of radix ampelopsis, 15-30 parts of vermilion, 6-12 parts of yellow leads and 15-30 parts of borneol which are mixed, crushed and sieved by the No.7 sieve. The sieved powder is placed in 60-120ml of rice vinegar to be uniformly stirred to form a paste product. The Chinese patent medicine provided by the invention simultaneously taken and applied is short in course of treatment, high in curative effect, low in treatment cost and simple in preparation method, and the patient has less pain.
PROBLEM TO BE SOLVED: To accumulate a large amount of γ-aminobutyric acid which is important as nervus inhibiting transmitter and showing the vasodepressor activity in the leaves of tea by irradiating the leaves of tea before steaming with infrared rays in the range of a wavelength with heating ability. SOLUTION: The leaves of tea before steaming are irradiated with infrared rays in the range of a wavelength (normally 650 to 2500nm) with heating ability. To pout it in the concrete, the leaves are irradiated with infrared rays while stirring tea leaves in the raw state by using a roughly crumpling device provided with the radiation source of infrared rays such as an infrared lamp, a far infrared heater, e.g. In addition the irradiating temp. of infrared rays is desirably controlled to make the temp. of the irradiated tear 40 to 50 deg.C. An irradiating time is desirably 20 to 60min in the above temp. condition.
The concomitant use of Hydrocodone Polistirex and Chlorpheniramine Polistirex and CYP3A4 inhibitors, such as macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g. ketoconazole), or protease inhibitors (e.g., ritonavir), can increase the plasma concentration of hydrocodone, resulting in increased or prolonged opioid effects. These effects could be more pronounced with concomitant use of Hydrocodone Polistirex and Chlorpheniramine Polistirex and CYP2D6 and CYP3A4 inhibitors, particularly when an inhibitor is added after a stable dose of Hydrocodone Polistirex and Chlorpheniramine Polistirex is achieved [see Warnings and Precautions (5.7)]. After stopping a CYP3A4 inhibitor, as the effects of the inhibitor decline, the hydrocodone plasma concentration will decrease [see Clinical Pharmacology (12.3)], resulting in decreased opioid efficacy or a withdrawal syndrome in patients who had developed physical dependence to hydrocodone.

Avoid the use of Hydrocodone Polistirex and Chlorpheniramine Polistirex while taking a CYP3A4 or CYP2D6 inhibitor. If concomitant use is necessary, monitor patients for respiratory depression and sedation at frequent intervals.
After surgical gingival depigmentation, injectable vitamin C (Redox C 500 mg) using insulin syringe(29 Gauge 1cc 0.33mm x 8mm 5/16 needle) is applied at gingival sites 0.1 ml for each point that should be 3 mm. The regimen is done once weekly for a month then once a month for additional 5 months.
The cloning, sequencing and expression of an M. pulmonis antigen, and the development of cloning and vaccination systems are disclosed. A strategy is described which allows the cloning of antigens despite the presence of codons which would normally cause transcription arrest in E. coli. Using this method, an M. pulmonis antigen was cloned and produced as a fusion protein, and the major epitope was identified. Transfection into lytic and lysogenic E. coli resulted in the production of the product. The antigen was shown to elicit antibody production in mice, including IgG and IgA production in the tracheolong lavage. Transfected lysogenic E. coli were used for vaccination. The production of the immunogen can be regulated in vivo by controlled feeding with the inducer, IPTG. This method of controlled vaccination, employing inducible immunizing agents, is proposed to be generally applicable to a wide range of organisms and diseases.
Participants will receive amivantamab 1050 milligram (mg) intravenously (IV) for body weight less than (\<) 80 kilogram (kg) and 1400 mg for body weight greater than or equal to (\>=) 80 kg in 28-day cycles: once weekly in Cycle 1 (with a split dose on Days 1-2), and then every 2 weeks in subsequent cycles. Lazertinib will be administered 240 mg (80\*3) orally once daily.
The present invention relates to a slightly acidic environment-sensitive and ketal-linked gefitinib axially substituted silicon phthalocyanine complex and a preparation method therefor and a medical use thereof. In particular, the present invention relates to a silicon phthalocyanine-gefitinib complex as shown in general formula (I) and a preparation method therefor and a pharmaceutical composition containing the complex, and the use thereof as a photosensitiser, especially the use in the treatment of cancers, wherein the definition of each substituent in general formula (I) is the same as that in the description. In a normal tissue environment, due to the interplay of the silicon phthalocyanine group and the gefitinib group, the complex has a lower cytotoxicity. However, in the extracellular slightly-acidic environment of the tumour tissue, ketals hydrolyse and the fragments of the hydrolysate, i.e. silicon phthalocyanine, exhibit an extremely high photosensitive activity, while another hydrolysate, i.e. a gefitinib derivative, can be used as an inhibitor of epidermal growth factor receptor (EGFR) tyrosinase for inhibiting tumour growth. The complexes can be prepared into photodynamic therapeutic and chemotherapeutic double-efficacy anticancer drugs targeting both the tumour extracellular slightly-acidic environment and the EGFR tyrosine kinase.
BACKGROUND: Dupilumab has demonstrate its potential to orchestrate inflammatory skin microenvironment, enhance skin barrier and shift skin microbiome dysbiosis, collectively contributing to clinical improvement in patients with atopic dermatitis (AD). As the second genome of human body, growing evidence suggests that the gut microbiome might relate to the host response to treatments. Little is known about the association between dupilumab treatment and gut microbiome in AD patients.
OBJECTIVE: We aimed to characterize the gut microbiome among Chinese subjects with or without AD and determine the potential effect of dupilumab on the gut microbiome.
RESULTS: The 16 s rRNA gene sequencing was conducted on 48 healthy controls (HC), 44 AD patients and 27 AD patients who received dupilumab for 16 weeks. Prior to treatment, we identified the changed beta-diversity, increased Firmicutes/Bacteroidetes ratio, decreased Bifidobacterium and expanded Faecalibacterium among the AD patients compared to HC. After 16 weeks of dupilumab treatment, gut microbiome dysbiosis of the AD patients improved with reversed beta-diversity, closer bacterial connections, increased colonization of Bifidobacterium, Ruminococcus gnavus, and Coprococcus, which were negatively correlated with disease severity indicators. This shift was largely independent of the degree of clinical improvement. Bacterial function analysis revealed further metabolic alterations following dupilumab treatment, including up-regulated expression of genes involved in the indole pathway of tryptophan metabolism, corroborated by quantitative UHPLC-MS/MS analysis.
CONCLUSION: Dupilumab treatment tends to help shift the gut microbial dysbiosis in AD patients to a healthier state, along with improved intestinal tryptophan metabolism, suggesting the gut flora and its metabolites may mediate part of the synergistic therapeutic effects on the host.
The study will invite nurses through QR code on line, and assess their background, self-efficacy, fear of COVID-19, psychological distress, and quality of life by questionnaires first. Then four evacuation acute wards (A, B, C, and D) will be randomly allocated, and the two wards will be drawn out as experimental group ward. Each group will be followed for 2 months and their outcomes will be assessed at 3 time points: baseline (pre-RPSG) (T0), and 4 (T1), 8 (T2) weeks after-RPSG, T0-T2, respectively.
Associations between HLA genotype and disease susceptibility encompass almost all the classic HLA loci. The level of typing resolution enabling a correct identification of an HLA disease susceptibility gene depends on the disease itself and/or on the accumulated knowledge about the molecular involvement of the HLA allele(s) engaged. Therefore, the application of Next Generation Sequencing technologies to HLA disease association, which would improve typing resolution, could prove useful to better understand disease severity. In the present study, we tested a nanopore sequencing approach developed by Omixon Biocomputing Ltd, dedicated to on-demand locus typing for HLA and disease, as an alternative to the conventional widely used sequence specific oligoprobe (SSO) approach. A total of 145 DNA samples used in routine diagnosis by SSO were retrospectively analyzed with nanopore technology, for HLA-A*02 immunotherapy decision for A*29, B*27, B*51, B*57 identification in class I, and DRB1, DQA1, and DQB1 for bullous dermatosis, rheumatoid arthritis, diabetes, and celiac disease requests in class II. Each locus was typed in a separate experiment, except for DQB1 and DQA1, which were analyzed together. Concordance between typings reached 100% for all the loci tested. Ambiguities by nanopore were only found for missing exon coverage. This approach was found to be very well adapted to the routine flow imposed by the SSO technique. This study illustrates the use of the new NanoTYPE MONO kit for single locus HLA sequencing for HLA and disease association diagnosis.
Experimental autoimmune encephalomyelitis (EAE) is an animal model of multiple sclerosis that shows demyelination in the central nervous system and functional deficits, including olfactory impairment. However, the genes related to olfactory impairment in EAE are unknown. We evaluated hub genes of the olfactory bulb in EAE mice. Differentially expressed genes (cut-offs, fold change > 2 and adjusted p < 0.05) and their related pathways in olfactory bulbs were subjected to gene ontology (GO) pathway analysis, gene set enrichment analysis (GSEA). Protein-protein interactions with selected genes were evaluated using the Search Tool for the Retrieval of Interacting Genes/Proteins. Gene regulatory networks (GRNs) which were constructed at the post-transcriptional level, including the genes-transcription factors (TFs) and gene-microRNAs (miRNAs) interaction networks. Twelve hub genes were found, three of which (Ctss, Itgb2, and Tlr2) were validated by RT-qPCR to be related to GO pathways such as immune response and regulation of immune response. GSEA showed that neuron-related genes-including Atp6v1g2, Egr1, and Gap43-and their pathways were significantly downregulated. GRNs analysis of six genes (Ctss, Itgb2, Tlr2, Atp6v1g2, Egr1, and Gap43) revealed 37 TFs and 84 miRNAs were identified as potential regulators of six genes, indicating significant interaction among six genes, TFs, and miRNAs. Collectively, these results suggest that transcriptomic analysis of the olfactory bulb of EAE mice can provide insight into olfactory dysfunction and reveal therapeutic targets for olfactory impairment.
The CASITA intervention was given by a community health worker (CHW) and involves individual and group modalities. HOME-CASITA took place at the dyad's place of residence, and the GROUP-CASITA at a local community center. All CASITA participants received 12 weekly sessions over 3 months. Interventions retain core elements of the SPARK approach: coaching parents on child development stimulation and providing social support and encouragement. Each session is as follows: 1) Child observation \& knowledge sharing about child development; 2) Practice of reciprocal attention focusing and social interaction activities; 3) Parent encouragement on behavior and developmental interactions; and 4) Parent social support through referral assistance, reassurance, and validation of parent's concerns.
Participants in the active control group (ARM2) of the PeCIC intervention will come to the behavioral testing laboratory to complete an 8-min control task every other day for 12 sessions. This control task is identical to the PeCIC except the auditory stop cues are omitted. All other procedures, settings, and schedules are identical to those in the experimental group. The only difference between the groups is that the active control does not practice IC.
Perioperative drug treatment has gradually become the standard regimen for locally advanced gastric cancer, whereas only a subset of patients could benefit from it. Therefore, one major challenge for perioperative drug treatment is to construct promising biomarkers and to screen out potential beneficial patients. Recent evidence has revealed that tumor microenvironment (TME) is highly associated with the prognosis of gastric cancer. Meanwhile, tumor microenvironment score (TMEscore) established with transcriptomic data is a robust biomarker for predicting prognosis and guiding individualized immunotherapy strategies. However, its predictive value for perioperative drug treatment outcomes warrants further exploration and validation. The study is a multi-center, observational study to evaluate the relationship between the efficacy of perioperative treatment and tumor microenvironment in patients with locally advanced resectable gastric and gastro-oesophageal junction adenocarcinoma, aiming at further determining the predictive value of TMEscore and establishing a comprehensive treatment-efficacy evaluation system for gastric cancer. Eligible subjects were selected according to the inclusion criteria and exclusion criteria. After the successful screening, the patients were treated in accordance with the clinical guidelines and the actual conditions. The residual tissue samples of the primary tumor were collected to conduct the tumor microenvironment detection. After routine neoadjuvant therapy, followed by a restaging of the tumor status and surgery. The residual surgical specimens were collected to conduct the tumor microenvironment detection analysis.
The invention discloses a traditional Chinese medicine composition for treating senile dementia and a preparation method of the traditional Chinese medicine composition. The traditional Chinese medicine composition for treating senile dementia comprises, by weight, 10-30 parts of gynostemma total saponins, 5-20 parts of panax notoginseng saponins, 2-10 parts of ginseng total saponins, 2-10 parts of epimedium total flavonoids and 2-12 parts of mulberry total flavonoids. The traditional Chinese medicine can remarkably relieve dementia symptoms and learning and memory disorders of a model mouse with senile dementia. Meanwhile, generation and deposition of pathological products, namely, beta-amyloid protein closely related to senile dementia can be remarkably inhibited. In addition, the inhibition effect of the traditional Chinese medicine composition is remarkably superior to that of the positive medicine, namely, huperzine. Accordingly, the traditional Chinese medicine composition for treating senile dementia is remarkably improved and can be used for preparing more advanced medicine for preventing and treating senile dementia.
A probiotic embedding particle and manufacturing method thereof are disclosed. The disclosed probiotic embedding particle comprises a probiotic sclerotium, a colloidal layer and a fungal hypha shell. The probiotic sclerotium is enclosed by the colloidal layer, and the colloidal layer is enclosed by the fungal hypha shell. The fungal hypha shell and the colloidal layer are functioned as an embedding structure that can effectively protect the probiotics. The fungal hypha shell comprises fungal nutrient substances which are capable of providing human body with health care effect when they are taken. Besides, with the structure of the fungal hypha shell, the stabilities of secondary processing and storage of the disclosed probiotic embedding particle can be increased. Further, the probiotic sclerotium can provide efficacies of body constitution adjustment, digestive functionality maintenance and gut microbiota variation, and the disclosed probiotic embedding particle can have a low manufacturing cost.
This is an open-label, multicenter, worldwide study to evaluate the contraceptive efficacy, safety, cycle control, compliance, and subject satisfaction of the transdermal patch compared with Triphasil. Fourteen hundred healthy women will receive study medication for either 6 or 13 cycles. The first 33% of subjects (\~265 transdermal patch subjects and 200 Triphasil subjects) will be expected to complete 13 cycles of medication. All subsequent subjects will be expected to complete 6 cycles. The ratio of subjects assigned to the transdermal patch arm of the study and to the Triphasil arm will be 4:3. At admission (Visit 1) study drug (plus 3 reserve patches), diary cards and subject instructions for Cycle 1 are dispensed. The first patch will be applied and Triphasil pill will be taken on the first day of menses. Study medication and diary cards will be issued on day 28 of Cycles 1 (Visit 2) and 3 (Visit 3), and those continuing for 13 cycles will receive study drug again (plus 3 reserve patches) on day 28 of Cycles 6 (Visit 4) and 9 (Visit 5). Diary cards and empty medication packages will be collected at every visit. Final visits are on day 28 of Cycles 6 and 9. Diary card information is used to record compliance and bleeding information (to assess cycle control). Contraceptive efficacy was assessed by means of the Pearl Index and life table analysis (gross cumulative probability of pregnancy). Safety evaluations were based on adverse events, which were collected throughout the study, and changes in physical examinations, gynecologic examinations, vital signs, and laboratory results from prestudy to final visit. A transdermal patch, containing 6 mg NGM and 0.75 mg EE, delivering 250 ug NGM and 25 ug EE over 24 hours for 7 days, is worn for 1 week and replaced for 3 consecutive weeks.The fourth week is patch-free. A Triphasil pill is taken for 28 consecutive days at the same time each day.
Veterinary compositions which are sterile injectable aqueous solutions or suspensions comprise as active ingredient not less than 0.5 per cent, e.g. 1 to 30 per cent by weight of cyanacethydrazide and at least one other ingredient which is of known veterinary utility when administered by injection such as antibacterial, antihelmintic or antiprotozoal agents, e.g. sulphonamide drugs such as sulphadimidine, penicillin preparations such as sodium or procaine penicillin G, 1-diethylcarbamyl-4-methyl-piperazine, or 6,61 - diquinolylurea dimethosulphate.  The composition may be prepared by preparing a sterile powder containing cyanacethydrin, at least one ingredient of known veterinary utility, and optionally an auxiliary agent, e.g. dispersing or antifloculation agents, and mixing said powder with a sterile aqueous medium, or the aqueous solution or suspension may be prepared by aseptic formulation or by Seitz filtration.  When the composition takes the form of a suspension the particulate matter may be of particle size substantially below 100 microns.  Specified dispersing or antiflocculation agents are sodium citrate, sodium carboxymethyl cellulose, polyglyceryl ricinoloate, disodium methylene - bis - naphthalene - 2 - sulphonate, phenol - ethylene oxide condensation products, e.g. the condensation product of octylcresol with 8 to 10 molecular proportions of ethylene oxide. Specification 817,380 is referred to.